Clik here to view.
Scientists and startups reveal new gene insertion techniques, though much...
Several secretive and well-funded biotechs are sharing the first glimpses of data from a new suite of gene editing tools that promise to overcome one of the field’s grand challenges: precisely...
View ArticleExcision BioTherapeutics’ attempt to gene edit HIV disappoints. The company...
BALTIMORE — HIV patients who received a CRISPR-based gene editing treatment developed by Excision BioTherapeutics saw the virus rebound, and now the company is going back to the lab to develop the...
View ArticleHouse Republicans put pressure on ASPR’s management of the national drug...
Lawmakers in the House Energy and Commerce Committee criticized the management of the national stockpile in a letter to the federal government’s Administration for Strategic Preparedness and Response...
View ArticleSenators question Chamber of Commerce's motives around march-in rights
Sens. Elizabeth Warren (D-MA), Bernie Sanders (I-VT) and Jeff Merkley (D-OR) accused a new US Chamber of Commerce coalition of attempting to “stymie the White House’s drug pricing initiatives.” The...
View ArticleNew Biosecure draft features 2032 grandfather clause, five-year grace period...
Drugmakers would have until 2032 to cut ties with WuXi AppTec and other Chinese life sciences companies, according to an updated draft of the closely watched Biosecure Act circulating ahead of the...
View ArticleTop stories from cell/gene therapy confab; 2032 deadline to decouple; Patient...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleSanofi, Pfizer, AstraZeneca, GSK to invest €2B+ in R&D, manufacturing in France
Sanofi, Pfizer and AstraZeneca separately pledged to increase their footprint in France, with investments adding up to almost €2 billion. GSK, AbbVie and Novartis are also allocating money to expand...
View ArticleClik here to view.
Sanofi buys ex-US rights to Fulcrum's Phase 3 rare neuromuscular drug
Sanofi will pay $80 million upfront to snag the ex-US license to Fulcrum Therapeutics’ rare neuromuscular disease treatment candidate, which will have Phase 3 data in the fourth quarter and potential...
View ArticleClik here to view.
Trailblazers, iconoclasts and breakthrough artists are coming to the...
Aviv Regev When Aviv Regev closed out one long chapter of her life at the Broad and stepped into a new job as head of research and early development at Genentech four years ago, she set out to build a...
View ArticleAjax gets $95M to test new JAK2 inhibitor after industry's series of...
A large pharma company wanted to buy Ajax Therapeutics when it was raising a $40 million Series B in 2021. But the startup thought it could do better on its own. “We thought that the compound at the...
View ArticleNewVale unveils $167M fund to back pharma service providers and 'old ideas...
Growth equity firm NewVale Capital officially broke cover with its $167 million fund on Monday morning to back third-party service providers that support the drug development industry. The Boulder,...
View ArticleCarolyn Bertozzi-founded Lycia Therapeutics raises $106M to enter the clinic
A different take on protein degradation will enter human trials as Lycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, has refueled with $106.6 million. The Series C, disclosed Monday...
View ArticleClik here to view.
Takeda bets $100M upfront on AC Immune's anti-amyloid Alzheimer's vaccine
AC Immune has lined up its third pharma partner in Alzheimer’s disease, and the pact comes with a hefty biobucks package. Takeda will pay AC Immune $100 million upfront to snag the exclusive option to...
View ArticleMerck winds down Phase 3 TIGIT/PD-1 combo study due to safety-related dropouts
A large number of patient dropouts caused by immune side effects have forced Merck to end a late-stage trial of its anti-TIGIT drug vibostolimab in skin cancer. Because of the dropouts, Merck unblinded...
View ArticleCytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep...
Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is already hiring medical affairs and payer interaction staff as it prepares for a...
View ArticleDeciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail...
Plus, news about OnKure: Deciphera’s other bidder: Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to a new SEC filing. In total,...
View ArticleClik here to view.
Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for...
Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored a $300 million investment...
View ArticleClik here to view.
Novo clears Phase 3 hemophilia A trial, plans to submit application by year's...
Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes....
View ArticleSize of 340B market triples since 2018 and may double again, report says
The battle between pharma companies and hospitals over the federal drug discount program known as 340B is gaining steam as its size has tripled since 2018 and may even double again, according to a new...
View ArticleClik here to view.
Shionogi misses primary endpoint in Phase 3 for Covid-19 antiviral
Shionogi’s once-daily Covid-19 antiviral ensitrelvir missed the primary endpoint in a Phase 3 study, two months after scoring full approval in Japan. In the NIH-partnered SCORPIO-HR study, ensitrelvir...
View Article